aTyr Pharma Inc
ATYR5.015USD
+0.315+6.70%
시장 운영 시간 （ET）시세는 15분 지연됩니다
446.35M시가총액
손실P/E TTM
자세한 내용은 aTyr Pharma Inc 회사
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0101 binds directly to latent-transforming growth factor beta-binding protein 1 (LTBP1), which regulates transforming growth factor beta (TGFb). Its ATYR0750 is a fusion protein derived from a domain of alanyl-tRNA synthetase (AARS).
회사 정보
종목 코드 ATYR
회사 이름aTyr Pharma Inc
상장일May 07, 2015
CEODr. Sanjay S. Shukla, M.D.
직원 수56
유형Ordinary Share
회계 연도 종료May 07
주소10240 Sorrento Valley Road
도시SAN DIEGO
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호92121
전화18587318389
웹사이트https://www.atyrpharma.com/
종목 코드 ATYR
상장일May 07, 2015
CEODr. Sanjay S. Shukla, M.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sara L. Zaknoen, M.D.
Dr. Sara L. Zaknoen, M.D.
Independent Director
Independent Director
--
--
Ms. Jill M. Broadfoot
Ms. Jill M. Broadfoot
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric S. Benevich
Mr. Eric S. Benevich
Independent Director
Independent Director
--
--
Ms. Nancy E. Denyes, J.D.
Ms. Nancy E. Denyes, J.D.
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Sanjay S. Shukla, M.D.
Dr. Sanjay S. Shukla, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
146.92K
--
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Chairman of the Board
Independent Chairman of the Board
56.00K
+833.33%
Dr. Jane A. Gross, Ph.D.
Dr. Jane A. Gross, Ph.D.
Independent Director
Independent Director
9.75K
+62.50%
Dr. Svetlana Lucas, Ph.D.
Dr. Svetlana Lucas, Ph.D.
Independent Director
Independent Director
6.00K
--
Dr. Paul R. Schimmel, Ph.D.
Dr. Paul R. Schimmel, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sara L. Zaknoen, M.D.
Dr. Sara L. Zaknoen, M.D.
Independent Director
Independent Director
--
--
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Fri, May 16
마지막 업데이트: Fri, May 16
주주
주주 유형
주주
주주
비율
Federated Hermes Global Investment Management Corp.
16.48%
Fidelity Management & Research Company LLC
14.49%
The Vanguard Group, Inc.
5.23%
Octagon Capital Advisors LP
3.99%
Point72 Asset Management, L.P.
3.20%
Other
56.62%
주주
주주
비율
Federated Hermes Global Investment Management Corp.
16.48%
Fidelity Management & Research Company LLC
14.49%
The Vanguard Group, Inc.
5.23%
Octagon Capital Advisors LP
3.99%
Point72 Asset Management, L.P.
3.20%
Other
56.62%
주주 유형
주주
비율
Investment Advisor
27.84%
Investment Advisor/Hedge Fund
20.75%
Hedge Fund
20.46%
Individual Investor
2.23%
Research Firm
1.92%
Pension Fund
0.20%
Bank and Trust
0.05%
Venture Capital
0.02%
Other
26.52%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
160
65.39M
73.47%
+2.57M
2025Q1
162
64.83M
72.99%
-691.51K
2024Q4
140
57.60M
68.66%
-6.81M
2024Q3
117
50.41M
67.53%
-11.03M
2024Q2
113
50.68M
74.24%
-3.06M
2024Q1
111
44.35M
66.05%
-8.23M
2023Q4
110
43.49M
75.20%
-5.05M
2023Q3
109
43.22M
76.15%
+288.84K
2023Q2
108
41.84M
78.83%
+2.15M
2023Q1
98
40.77M
78.21%
+15.80M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Federated Hermes Global Investment Management Corp.
14.67M
16.48%
--
--
Mar 31, 2025
Fidelity Management & Research Company LLC
12.89M
14.49%
+796.10K
+6.58%
Mar 31, 2025
The Vanguard Group, Inc.
4.01M
4.5%
+401.81K
+11.15%
Mar 31, 2025
Octagon Capital Advisors LP
3.55M
3.99%
+2.65M
+294.67%
Mar 31, 2025
Point72 Asset Management, L.P.
2.84M
3.2%
-2.04M
-41.76%
Mar 31, 2025
Tikvah Management LLC
2.46M
2.76%
--
--
Mar 31, 2025
Susquehanna International Group, LLP
1.73M
1.95%
+945.24K
+119.98%
Mar 31, 2025
Woodline Partners LP
1.68M
1.89%
-1.41K
-0.08%
Mar 31, 2025
UBS Financial Services, Inc.
1.61M
1.81%
+1.38M
+600.20%
Mar 31, 2025
Millennium Management LLC
1.60M
1.8%
+1.23M
+334.53%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
Invesco Dorsey Wright SmallCap Momentum ETF
0.42%
iShares Micro-Cap ETF
0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.03%
ProShares Hedge Replication ETF
0.02%
ProShares UltraPro Russell2000
0.02%
iShares Russell 2000 Growth ETF
0.02%
Global X Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
iShares Russell 2000 ETF
0.01%
iShares Russell 2000 Value ETF
0%
더 보기
Invesco Dorsey Wright SmallCap Momentum ETF
비율0.42%
iShares Micro-Cap ETF
비율0.1%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
비율0.03%
ProShares Hedge Replication ETF
비율0.02%
ProShares UltraPro Russell2000
비율0.02%
iShares Russell 2000 Growth ETF
비율0.02%
Global X Russell 2000 ETF
비율0.02%
Proshares Ultra Russell 2000
비율0.02%
iShares Russell 2000 ETF
비율0.01%
iShares Russell 2000 Value ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
